Questions

Lumyx Health is a physician-led platform being built to help women navigate perimenopause, menopause, and the years beyond — while helping clinicians provide more informed, connected care. It will bring symptoms, cycles, health history, laboratory results, treatments, and personal priorities into one view for women, while supporting clinicians with concise context and reviewed evidence. Lumyx is designed to strengthen, not replace, clinical judgment or the relationship between a woman and her clinician.

Lumyx is more than a symptom tracker, content library, chatbot, or one-size-fits-all menopause clinic. It will connect two experiences: women can build a clearer health story, and, with their authorization, clinicians can review a concise summary supported by trusted evidence. By connecting preparation, the visit, and follow-up, Lumyx will help women and clinicians use their time together more meaningfully, while closing the knowledge gap around midlife care for women.

Lumyx is being designed for women navigating perimenopause, menopause, and postmenopause — and for the clinicians and organizations that care for them. For women, it will look beyond hot flashes to sleep, mood, cognition, menstrual changes, sexual and urinary health, metabolism, bone and heart health, gynecologic concerns, and prevention. For clinicians and organizations, it will offer a clearer clinical picture, evidence-informed support, and a more useful starting point for care.

See the full picture. Lumyx will help women bring together symptoms, cycles, health history, treatments, selected laboratory results, priorities, and questions — so important details are easier to understand and less likely to be overlooked. Come prepared. Women can review and edit their information, then decide what to share. Clinicians can quickly see the concerns, patterns, and context that matter most, with relevant evidence to support — not replace — their clinical judgment. Stay connected over time. Lumyx will help women and clinicians follow symptoms, treatment response, decisions, education, and next steps, so each visit begins with a clearer understanding of what has changed.

Lumyx Health was founded and is led by a board-certified OB-GYN with more than a decade of experience in private practice and hospital care. A multidisciplinary team brings expertise in clinical care, product development, technology, design, privacy, and security. Lumyx grew from seeing women's midlife concerns fragmented across symptoms, specialists, and short visits. The team is building a clearer way for women and clinicians to see the full picture together.

Lumyx will help you organize and understand what has changed, what you have tried, what matters most, and the questions you want answered. You can review and edit an appointment-ready summary, giving you and your clinician a clearer place to begin.

Yes. Lumyx is being built to support the clinician you already know and trust. When available, you can choose whether to share a concise summary; your clinician will decide how to use it within your care.

Lumyx is expected to launch as a subscription, priced to reflect ongoing evidence review, platform support, and the connection it creates with your clinician — not a one-time app purchase. Final pricing and any plan options will be confirmed and published before launch.

Lumyx is currently in development. Joining the waitlist is the fastest way to hear when features become available, and early members may be invited to try the platform ahead of general access.

No. Lumyx will not independently diagnose, prescribe, or choose treatment. It will organize the information you provide, offer education from reviewed sources, and help you prepare questions. Diagnosis and treatment decisions remain with you and an appropriately licensed healthcare professional.

Not at this time. Lumyx is developing its technology, education, and care-support platform; the website, survey, and waitlist do not provide care or create a clinician-patient relationship. Any future clinical services will be introduced separately and delivered by appropriately licensed professionals where authorized.

Lumyx is being designed to keep you in control of your information. You can review or correct it and choose what to share and with whom. Personal tracking will remain separate from information you authorize for clinical use, with permissions and privacy practices explained clearly.

No. Lumyx is not an emergency service and should never delay care for severe, sudden, or worsening symptoms. Call 911 or go to the nearest emergency department for an emergency. Heavy or unusual bleeding, severe pain, pregnancy-related concerns, or anything that feels serious should be evaluated promptly by a qualified medical professional.

With the woman's authorization, Lumyx may give clinicians a concise view of symptoms, cycles, relevant history, medications and treatments, priorities, and changes over time, with efficient access to reviewed evidence and clinical care pathways. The goal is a more productive visit without replacing the clinician's assessment, documentation, or judgment.

No. Lumyx can organize information and surface relevant evidence, but clinicians remain responsible for assessment, diagnosis, treatment, prescribing, documentation, follow-up, and escalation. They can review why information appears, then accept, modify, or disregard it for the individual patient.

Lumyx is developing a governed evidence library rather than relying on one guideline or a static article collection. Content and pathways will link to identifiable sources, dates, reviewers, safety exclusions, test cases, change histories, and review schedules informed by sources such as The Menopause Society and the American College of Obstetricians and Gynecologists (ACOG), alongside other evidence-based sources and relevant peer-reviewed evidence.

AI will have a defined, assistive role: organizing patient-reported information, identifying patterns for review, retrieving approved content, and summarizing reviewed evidence. It will not independently diagnose, prescribe, invent guidance, change patient information silently, or make treatment decisions. Important outputs should be labeled, editable, traceable to their sources, and open to clinician review; urgent or high-risk pathways will not rely on generative AI alone.

Lumyx is being designed to make limited visit time more useful. Women can organize key information beforehand, giving clinicians a concise view of the concerns and context that matter most. Workflow and interoperability will be tested with clinicians and healthcare organizations before broader use, with the goal of reducing duplicate work, strengthening the patient-clinician relationship, and supporting more informed, accessible care.

Lumyx welcomes input from OB-GYNs, primary care and family medicine clinicians, advanced practice clinicians, pharmacists, behavioral health professionals, and other midlife-care experts. Opportunities may include interviews, advisory work, evidence review, usability and workflow testing, research, or future design-partner and pilot programs. The clinician waitlist is coming soon, and each opportunity will define its role and expectations.

Lumyx is not offering a finished, one-size-fits-all rollout. Current collaboration focuses on listening, responsible co-design, research, workflow testing, education, and planning for future pilots. Organizations can explore a defined opportunity shaped by their population, clinical environment, and governance requirements.

Potential collaborators include health systems, physician groups, academic and residency programs, employers, benefit organizations, professional societies, research partners, and community organizations serving women in midlife or their clinicians. The best fit is a partner with a genuine need and an interest in providing meaningful value.

Women often repeat months or years of symptoms across separate visits while clinicians must make sense of them quickly. Evidence, education, and follow-up may also be fragmented. Lumyx is designed to organize the story, support better-prepared visits, make reviewed evidence easier to use, and preserve continuity over time.

A future pilot would begin with a focused question, defined population, and agreed measures. Depending on the partner and stage, it might evaluate usability, workflow fit, visit preparation, engagement, clinician experience, education, or follow-up. Roles, data use, privacy, security, clinical safety, escalation, and required approvals would be established before implementation.

Lumyx is open to carefully designed research and quality-improvement collaborations that advance midlife health and care delivery. Projects involving patient information, research, or identifiable health data would require appropriate agreements, consent or authorization, safeguards, governance, and institutional or regulatory review when applicable. Research, quality improvement, and product testing would be identified distinctly.

Privacy, safety, and governance are being built in from the start. Lumyx is designed around patient-controlled sharing, clear clinical boundaries, reviewable evidence, clinician judgment, data minimization, and appropriate privacy and security controls. Relevant legal, regulatory, clinical-safety, privacy, and security requirements must be implemented and assessed before deployment. Lumyx will make compliance claims only when the necessary people, processes, technology, and data flows are in place.

Lumyx is being designed to collect only what is needed for a defined purpose and limit access by role. Planned protections include patient-controlled sharing, clear permissions, technical safeguards, auditability, security risk assessment, and use limits. Safeguards will depend on each implementation. When Lumyx acts as a business associate, appropriate Business Associate Agreements and applicable HIPAA obligations would apply; privacy and compliance claims will follow verification.

No. Lumyx will not sell personal or health information, and it is not being built to support third-party advertising. Any sharing of information will be limited to what a woman authorizes for her own care, what a business associate arrangement requires, or what is necessary to operate the platform, and will be explained clearly in Lumyx's privacy practices.

Technology can support care, but it cannot practice medicine. If clinical services are introduced, licensed clinicians and the appropriate professional entity will remain responsible for assessment, medical decisions, prescribing, records, informed consent, quality oversight, follow-up, and escalation. Lumyx technology will not override those responsibilities.

If Lumyx later offers clinical services, the patient's location at the time of care will help determine applicable laws and medical board requirements. Services would be available only where the clinician and professional entity are authorized, and requirements may include licensure, scope, consent, prescribing, records, privacy, continuity, and emergency planning. Availability may vary by state and clinician. Educational or organizational tools are not medical care.

Lumyx is developing governance that preserves the source, version, rationale, reviewer, and change history behind clinical content. It will distinguish user-entered from verified information, maintain appropriate access and audit records, support clinician review and override, and document safety exclusions and material changes.

Lumyx Health is developing the platform, education, brand, and administrative technology. Any future clinical services will be delivered through an appropriate professional structure by properly licensed clinicians. Medical decisions, prescribing, professional records, quality, and supervision will remain within that clinical structure, protecting clinical independence and accountability.

Lumyx welcomes early dialogue with state medical boards, regulators, professional organizations, patient-safety experts, academic institutions, and other stakeholders. The goal is to hear concerns early, build appropriate safeguards, and respect patient autonomy, professional accountability, state oversight, and the limits of clinical decision support. Dialogue or collaboration does not imply regulatory endorsement, approval, or authorization. Publication Notes IMPORTANT This is a strategic website draft. Before final publication, statements about healthcare delivery, HIPAA, state licensure, clinical decision support, artificial intelligence, privacy, security, prescribing, research, and regulatory status will need to be reviewed against the product's implemented capabilities and applicable law. Suggested Calls to Action For women: Join the Lumyx waitlist to be among the first to try a clearer way to prepare for appointments and track your midlife health. For clinicians: Express interest in clinical collaboration and help shape the evidence and workflows before they reach your patients. For organizations: Explore a design-partner conversation and shape a pilot built around your population and governance requirements from day one. For regulatory stakeholders: Contact Lumyx about governance and responsible innovation, and start the dialogue early, before deployment decisions are made. General contact: info@lumyxhealth.com